Akouos Inc. (AKUS): Price and Financial Metrics


Akouos Inc. (AKUS): $13.29

0.14 (+1.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AKUS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AKUS Stock Price Chart Interactive Chart >

Price chart for AKUS

AKUS Price/Volume Stats

Current price $13.29 52-week high $13.60
Prev. close $13.15 52-week low $2.32
Day low $13.16 Volume 1,790,400
Day high $13.33 Avg. volume 344,411
50-day MA $10.65 Dividend yield N/A
200-day MA $5.54 Market Cap 490.88M

Akouos Inc. (AKUS) Company Bio


Akouos, Inc. engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna in 2017 and is headquartered in Boston, MA.


AKUS Latest News Stream


Event/Time News Detail
Loading, please wait...

AKUS Latest Social Stream


Loading social stream, please wait...

View Full AKUS Social Stream

Latest AKUS News From Around the Web

Below are the latest news stories about AKOUOS INC that investors may wish to consider to help them evaluate AKUS as an investment opportunity.

Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.

Yahoo | December 1, 2022

Lilly and Akouos Announce Expiration of Akouos Tender Offer

Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockh

Yahoo | November 30, 2022

10 Most Promising Gene Therapy Companies to Watch

In this piece, we will take a look at the ten most promising gene therapy companies to watch. For more companies, take a look at 5 Most Promising Gene Therapy Companies to Watch. Gene therapy is a revolutionary new technology that has followed the growing advances in computing power. The human body is estimated to […]

Yahoo | November 14, 2022

Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights

-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss w

Yahoo | November 14, 2022

The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVie

J&J, Roche, Eli Lilly and AbbVie are part of The Zacks top Analyst Blog.

Yahoo | October 24, 2022

Read More 'AKUS' Stories Here

AKUS Price Returns

1-mo N/A
3-mo 0.91%
6-mo 311.46%
1-year 132.34%
3-year N/A
5-year N/A
YTD N/A
2022 0.00%
2021 -57.14%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6665 seconds.